Roche Enjoined In Patent Battle With Amgen

Law360, New York (February 29, 2008, 12:00 AM EST) -- Roche Holdings AG has been preliminarily barred from selling the anemia drug Mircera in the U.S. while the court considers granting Amgen Inc.'s bid for a permanent injunction.

U.S. District Judge William G. Young of the U.S. District Court for the District of Massachusetts entered an order Thursday saying that the jury verdict in the case “will stand in all respects” and enjoining Roche from infringing Amgen's patents until they expire.

In October 2007, a jury found that Mircera infringed three Amgen patents, and in August...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.